ライフサイエンスコーパス: immunosuppressive

1 genous retroviruses is considered inherently immunosuppressive.

2 Previous work has implicated JH as immunosuppressive [12, 13], and the male seminal fluid p

3 tress; 6) induce chronic inflammation; 7) be immunosuppressive; 8) modulate receptor-mediated effects

4 atherosclerotic-MSCs improve their in vitro immunosuppressive ability and may translate into enhance

5 local ablative radiation that relies on the immunosuppressive action of STING.

6 Recapitulation of essential immunosuppressive activities of IL-35 indicates that IL-

7 amily of molecules harbors antimicrobial and immunosuppressive activities, and its pathway is respons

8 Targeting c-Rel blunts Treg cell immunosuppressive activity in the tumor microenvironment

9 tic strategies to block the accumulation and immunosuppressive activity of such cells may help preven

10 -infiltrating CCR5(+) MDSCs displayed higher immunosuppressive activity than their CCR5(-) counterpar

11 Extensive work mapped the immunosuppressive activity to a highly conserved domain,

12 turally polymorphic key residues that afford immunosuppressive activity to distinct envelope glycopro

13 found in some envelope glycoproteins lacking immunosuppressive activity were shown to affect retrovir

14 ls of PD-L1, CD39, and CD73 exerted a robust immunosuppressive activity, relative to other myeloid ce

15 One such example is a putative immunosuppressive activity, which has been mapped to a c

16 (F-MLV) ISD has been reported to abolish its immunosuppressive activity, without affecting its fusoge

17 redicted the magnitude of IFN-gamma-enhanced immunosuppressive activity.

18 ed slower population doubling and a stronger immunosuppressive activity.

19 tical, because while chronic stress is often immunosuppressive, acute stress can temporarily enhance

20 Increasing evidence exists for the role of immunosuppressive adenosine in promoting tumor growth an

21 accumulation of immunostimulatory ATP versus immunosuppressive adenosine within the tumor microenviro

22 induction of CD73, the enzyme that generates immunosuppressive adenosine, is linked to melanoma pheno

23 Although interest surrounds use of immunosuppressive agents added to standard therapy, seve

24 the data available on the risk of individual immunosuppressive agents and their ability to prevent dn

25 long-term safety for this approach, when the immunosuppressive agents were antimetabolites or calcine

26 rrently being treated using corticosteroids, immunosuppressive agents, and biotherapies.

27 r plasma exchange, often in combination with immunosuppressive agents, for acquired TTP.

28 mmune disease requiring systemic steroids or immunosuppressive agents, had no active non-infectious p

29 were closely monitored for trough levels of immunosuppressive agents, laboratory values, and potenti

30 nesis, as shown by successful treatment with immunosuppressive agents, leading to transfusion indepen

31 tumor growth and are influenced by different immunosuppressive agents.

32 covirus) are presented here because they are immunosuppressive and affect health in domesticated anim

33 impressive and effective anti-inflammatory, immunosuppressive and anti-tumor activities.

34 The prolbenes lacked immunosuppressive and antimicrobial activities compared

35 ost, how it is modified by variables such as immunosuppressive and antimicrobial drugs, and its poten

36 a resistant HIV strain, determining optimal immunosuppressive and antiretroviral regimens, and eluci

37 IMPDH is the target of drugs with antiviral, immunosuppressive and antitumor activities, its physiolo

38 However, current therapies are primarily immunosuppressive and lack selectivity and efficacy.

39 mote lung cancer progression by fostering an immunosuppressive and prometastatic tumor microenvironme

40 hat these compounds are immunoregulatory and immunosuppressive and thus may increase susceptibility t

41 These PD-L1-expressing cells were immunosuppressive and were capable of eliminating CD8 T

42 will be persistently increased, functionally immunosuppressive, and associated with adverse clinical

43 SCs are persistently increased, functionally immunosuppressive, and associated with adverse outcomes.

44 ventions are targeting the inflammatory, the immunosuppressive, and the protein catabolic responses i

45 AC)-based regimens are the most common among immunosuppressive approaches used in in clinical practic

46 nd increased cytotoxicity in the presence of immunosuppressive ascites.

47 (+) T cells marked by high expression of the immunosuppressive ATP ecto-nucleotidase CD39.

48 Similarly, disruption of this tumour immunosuppressive axis by specifically blocking PGD2, IL

49 favor of strategies that specifically target immunosuppressive blood-derived TAMs.

50 data suggest that PTCy minimizes the global immunosuppressive burden experienced by patients undergo

51 ould be translatable to the clinic and other immunosuppressive cancers.

52 and 2 in the MSC secretome and improved MSCs immunosuppressive capacity (P=0.03).

53 ma stimulation significantly correlated with immunosuppressive capacity and accurately predicted the

54 single-cell morphological data with overall immunosuppressive capacity in a cohort of MSC lines deri

55 To identify features associated with immunosuppressive capacity in MSCs, we developed a robus

56 IFN-gamma enhanced the immunosuppressive capacity of all MSC lines, and morphol

57 essive capacity and accurately predicted the immunosuppressive capacity of MSC lines in a validation

58 ell phenotype, immune function, and CLL cell immunosuppressive capacity were evaluated.

59 ssue repair in a manner separable from their immunosuppressive capacity.

60 cellular prion protein CD230/PrP(C) and the immunosuppressive cell surface enzyme ecto-5'-nucleotida

61 ngly, alpha-4-1BB significantly reduced host immunosuppressive cells at the tumor site, including reg

62 T lymphocytes and macrophages both display immunosuppressive characteristics: T cells with a regula

63 is combined with a decreased sensitivity to immunosuppressive checkpoint pathways to provide greater

64 te did not differ between patients receiving immunosuppressive combination and controls on supportive

65 including donor-specific antibody) patients, immunosuppressive combinations that are better tolerated

66 nidentified immunostimulatory bioactives and immunosuppressive components; the bioavailability of som

67 Patients with cancer or immunosuppressive conditions and residents of long-term

68 of proapoptotic gene expression, because the immunosuppressive consequence attributed to the absence

69 .81; 95% CI, 1.25-18.56; P = .02) and use of immunosuppressive corticosteroids (OR, 13.42; 95% CI, 1.

70 In ovarian cancer, this is in part due to an immunosuppressive cytokine and cellular tumor microenvir

71 Conversely, the immunosuppressive cytokine IL-10 has been shown to dampe

72 l receptor (TCR), express high levels of the immunosuppressive cytokine IL-10, but not Foxp3, and can

73 peutics in diverse ways such as secretion of immunosuppressive cytokines and expression of immune inh

74 patients showed elevated levels of M2-skewed immunosuppressive cytokines and pregnancy-complication-a

75 Blood-derived TAMs upregulate immunosuppressive cytokines and show an altered metaboli

76 ype of microglia, but preferentially express immunosuppressive cytokines and show an altered metaboli

77 RPS19 also induces the production of immunosuppressive cytokines, including TGF-beta, by myel

78 ent, and that they express genes that encode immunosuppressive cytokines, such as IL-4 and IL-10.

79 r risk of fungal infections in patients with immunosuppressive disease.

80 ity to a highly conserved domain, termed the immunosuppressive domain (ISD), in the transmembrane (TM

81 Monitoring of creatinine and immunosuppressive drug concentrations, such as tacrolimu

82 ies a binding pocket on PP2B utilized by the immunosuppressive drug cyclosporin.

83 ced major immune insults, particularly prior immunosuppressive drug exposure.

84 nhibitor, rapamycin, is currently used as an immunosuppressive drug in transplant patients, it has be

85 en generic and brand-name formulations of an immunosuppressive drug in transplant recipients.

86 Immunosuppressive drug therapy lowered the risk of visua

87 topical corticosteroid use, and concomitant immunosuppressive drug use.

88 Sirolimus (rapamycin) is an immunosuppressive drug used in transplantation.

89 Nephrotoxicity side effect of the immunosuppressive drug, cyclosporine A (CsA), can be a m

90 ical therapy with tacrolimus, an anti-T-cell immunosuppressive drug, is highly effective in preventin

91 In addition, many of the immunosuppressive drugs are diabetogenic.

92 We confirm that the immunosuppressive drugs cyclosporine and tacrolimus also

93 Eliminating the need for nephrotoxic immunosuppressive drugs during the early posttransplant

94 The pharmacokinetics (PK) studies of immunosuppressive drugs in healthy volunteers, rarely, i

95 provide new understanding of how widely used immunosuppressive drugs interfere with essential process

96 Treatment with immunosuppressive drugs lowered the risk of visual loss.

97 , whereas 8 and 13 patients received various immunosuppressive drugs or symptomatic measures alone, r

98 s (antithymocyte globulin [ATG]) are popular immunosuppressive drugs used to prevent or treat organ o

99 imary endpoint was freedom from all systemic immunosuppressive drugs without resumption up to 12 mont

100 se in almost all patients without additional immunosuppressive drugs, as seen in the Study of Thymogl

101 lograft rejection in the absence of systemic immunosuppressive drugs.

102 s, via dietary management, or as adjuncts to immunosuppressive drugs.

103 inhibit neointimal proliferation by eluting immunosuppressive drugs.

104 e that radiation-induced STING activation is immunosuppressive due to (monocytic) M-MDSC infiltration

105 negative and neutral charged NPs exhibit an immunosuppressive effect but that positively charged NPs

106 ration, arguing for their involvement in the immunosuppressive effect of BECs.

107 alpha and IFNbeta (type I IFNs) reversed the immunosuppressive effect of MSCs on splenocyte prolifera

108 Here, we evaluate whether the immunosuppressive effect of reproduction in female D. me

109 t the site of infection and exerted a potent immunosuppressive effect on T-cell responses that was me

110 n kidney epithelial cells did not induce the immunosuppressive effects observed with prednisolone.

111 rom MS patients were more susceptible to the immunosuppressive effects of cannabinoids than those fro

112 Furthermore, the immunosuppressive effects of radiotherapy and STING agon

113 antagonism between the immunostimulatory and immunosuppressive effects of RT as we delineate combinat

114 CBD showed higher immunosuppressive effects than THC.

115 e expressed during lytic infection and cause immunosuppressive effects that impede virus clearance.

116 These immunosuppressive effects were all reversed by CD73 bloc

117 vated via CAR stimulation and exerted potent immunosuppressive effects when stimulated in vitro.

118 high-dose prednisolone without the systemic immunosuppressive effects.

119 ulate Th cell responses and to determine the immunosuppressive efficacy of RASF.

120 tumor-specific CTLs and curtailment of tumor immunosuppressive environment.

121 leamine 2,3-dioxygenase (IDO-1) to induce an immunosuppressive environment.

122 sed AML patients contains elevated levels of immunosuppressive exosomes which interfere with anti-leu

123 s in tumors, and inhibited the expression of immunosuppressive factors arginase I and iNOS.

124 Glioblastoma is an immunosuppressive, fatal brain cancer that contains glio

125 t that T-bet(+) Treg cells have an essential immunosuppressive function and indicate that Treg cell f

126 In cancer, it exerts an immunosuppressive function as part of an acquired mechan

127 Our study unveils an immunosuppressive function of Ly6Clo monocytes that, to

128 eloid cells and found that Tet2 sustains the immunosuppressive function of these cells.

129 dalities for target genes related to classic immunosuppressive function vs. those related to atypical

130 SC morphology as a predictive feature of MSC immunosuppressive function.

131 ory one, with a concomitant reduction of the immunosuppressive function.

132 ent but also for further activation of their immunosuppressive functions in the tumor microenvironmen

133 twithstanding, type I IFNs also exert potent immunosuppressive functions.

134 ssed melanoma growth in vivo and shifted the immunosuppressive gene expression program in tumor-assoc

135 and, while hyperinfection can be induced by immunosuppressive glucocorticoids, the pathogenesis rema

136 Although all Foxp3-expressing subsets are immunosuppressive, glycolysis is a prominent metabolic p

137 ther, these data confirm the existence of an immunosuppressive gradient across the TME, NTME, and per

138 SC), which are a heterogeneous population of immunosuppressive immature myeloid cells, expanded durin

139 ll death (ICD) as well as interfering in the immunosuppressive indoleamine 2,3-dioxygenase (IDO) path

140 CXCR4 was predominantly expressed in immunosuppressive innate immune cells, which are recruit

141 Transplant recipients are treated with immunosuppressive (IS) therapies, which impact host-micr

142 D90+ cells showed enhanced expression of the immunosuppressive ligand PD-L1, a higher constitutive se

143 among tumor-associated macrophages from the immunosuppressive M2-like phenotype to the inflammatory

144 cell responses and decreased infiltration of immunosuppressive MDSC.

145 IDO-1 is a nexus for the induction of a key immunosuppressive mechanism and represents an important

146 T-cell inhibitory receptor PD-1, is one key immunosuppressive mechanism by which cancer avoids eradi

147 se results suggest that HHLA2 may be a novel immunosuppressive mechanism within the osteosarcoma tumo

148 mploying a balancing act of inflammatory and immunosuppressive mechanisms designed to neutralize fore

149 ful to date, partly because of tumor-induced immunosuppressive mechanisms, including adenosine produc

150 ared infecting bacteria, and did not express immunosuppressive mediators.

151 C (ribavirin and interferon) in addition to immunosuppressive medical and surgical treatment which r

152 azard and greater chances of nonadherence to immunosuppressive medication after HTx, but the elevatio

153 Whether the immunomodulatory and immunosuppressive medication against hepatitis C was the

154 risk attributed to increased nonadherence to immunosuppressive medication in this age window.

155 le questionnaires were administered to gauge immunosuppressive medication-related side effects in the

156 surgical interventions, endoscopies, PN, and immunosuppressive medication.

157 She was not taking any anticoagulants or immunosuppressive medication.

158 cell carcinoma (BCC), in part as a result of immunosuppressive medications administered to prevent gr

159 He remains on four immunosuppressive medications and functional neuroimagin

160 tinal drug absorption of orally administered immunosuppressive medications posttransplant is critical

161 for autoimmune diseases rely on traditional immunosuppressive medications that expose patients to an

162 Extracellular adenosine is a key immunosuppressive metabolite that restricts activation o

163 s and suppresses CD8 T cells to establish an immunosuppressive microenvironment conducive to metastas

164 protein (Yap) as a critical regulator of the immunosuppressive microenvironment in both mouse and hum

165 CAR T cells; second, solid tumors create an immunosuppressive microenvironment that inactivates T ce

166 ostic biomarker and a crucial determinant of immunosuppressive microenvironment via recruiting Treg c

167 multiple molecules engaged in developing the immunosuppressive microenvironment, including galectin-1

168 s is limited by their ability to engender an immunosuppressive microenvironment.

169 gnaling, presenting with proinflammatory and immunosuppressive microenvironments and spontaneous live

170 Our hypothesis is that immunosuppressives might affect airway integrity.

171 t induce cell surface expression of CD39, an immunosuppressive molecule that can be therapeutically t

172 Both agents reduced expression of the immunosuppressive molecules CD200 and BTLA as well as IL

173 s a combination of immune activation and the immunosuppressive mTOR inhibitor rapamycin.

174 cytotoxicity and decreased the frequency of immunosuppressive myeloid-derived suppressor cells in a

175 y, we observed that the previously described immunosuppressive neutrophil population that appears in

176 e are exposed to either cancer chemotherapy, immunosuppressive or biologic therapies for the manageme

177 b(+) neutrophil populations, exerting either immunosuppressive or proinflammatory functions, has been

178 owever, is likely blunted by the presence of immunosuppressive pathways within the microenvironment,

179 sociated growth factors, fibrosis-associated immunosuppressive pathways, as well as mechanosensitive

180 obial factors and to identify protective and immunosuppressive pathways.

181 Moreover, they exhibited a stronger immunosuppressive pattern compared with CCR5(-) MDSCs.

182 presentation, and fewer macrophages with an immunosuppressive phenotype in tumors.

183 ice in enriched environment (EE) reverts the immunosuppressive phenotype of infiltrating myeloid cell

184 tantly, also in the presence of TKIs, the M2 immunosuppressive polarization was reverted by TLR engag

185 nd was associated with reduced migration and immunosuppressive potential of MDSCs in tumor lesions.

186 In this article, we report novel immunosuppressive properties of the ribosomal protein S1

187 ion of monoclonal antibodies against TNF has immunosuppressive properties via effects on macrophage p

188 (itBreg) cells are innate-like B cells with immunosuppressive properties, and the in vivo mechanisms

189 n HCT recipients who developed GVHD while on immunosuppressive prophylactic agents recapitulated the

190 The immunosuppressive protein PD-L1 is upregulated in many c

191 The initial immunosuppressive protocol included thymoglobulin, tacro

192 opsy, dual KT, machine perfusion and special immunosuppressive protocols.

193 Current chronic use of immunosuppressive reagents for preventing islet allograf

194 ients were mimicked by treating pigs with an immunosuppressive regimen including cyclosporine, azathi

195 imus, basiliximab, and mycophenolate mofetil immunosuppressive regimen is efficacious, with a low inc

196 Neither immunosuppressive regimen prevented GFR loss, and both a

197 he first year were more frequent with either immunosuppressive regimen than with supportive care.

198 cineurin inhibitor (CNI)-lowered or CNI-free immunosuppressive regimen using everolimus (EVR), but th

199 informative data about the risk of different immunosuppressive regimens, including biologics, on HBV

200 ts and thereby, aid clinicians in optimizing immunosuppressive regimens.

201 k of progression differs between viruses and immunosuppressive regimens.

202 hat commonly used postkidney transplantation immunosuppressive regimes may be prescribed after total

203 tment improved the impaired dentinogenic and immunosuppressive regulatory functions of disease-derive

204 ion mechanisms, including activation of host immunosuppressive regulatory T (Treg) cells.

205 An imbalance in the lineages of immunosuppressive regulatory T cells (Treg cells) and th

206 deployment of both a pro-inflammatory and an immunosuppressive response in the skin.

207 ffects capable of inhibiting ACD by inducing immunosuppressive responses.

208 Here, we have uncovered an immunosuppressive role for nonclassical Ly6Clo monocytes

209 h-ligand 1 (PD-L1) pathway play an important immunosuppressive role in cancer and chronic viral infec

210 tif-containing (TRIM)-28 is known to have an immunosuppressive role in immune cells, its expression l

211 k, BECs are also suspected to play a pivotal immunosuppressive role in T cell alloreactivity.

212 crovascular endothelial cells was exposed to immunosuppressives (serum through levels) for 24 hours o

213 t that the tumor microenvironment creates an immunosuppressive signature on tumor-associated macropha

214 Lnc-EGFR links an immunosuppressive state to cancer by promoting Treg cell

215 l in preventing autoimmunity and is a potent immunosuppressive stimulus.

216 Thus, immunosuppressive strategies for lung transplant recipie

217 apeutic approaches involve potentially toxic immunosuppressive strategies, the pathophysiology remain

218 Mycophenolic acid (MPA) is the active immunosuppressive substance in both mycophenolate mofeti

219 FH frequency and function, and also promotes immunosuppressive T follicular regulatory cells (TFR).

220 In the healthy steady state, a population of immunosuppressive T-cells called regulatory T-cells (Tre

221 tivity and is associated with a reduction in immunosuppressive T-cells.

222 crophages (TAMs) are abundant in gliomas and immunosuppressive TAMs are a barrier to emerging immunot

223 t can coordinately neutralize the effects of immunosuppressive TGFbeta in the tumor microenvironment

224 ogenic pathway that may represent a relevant immunosuppressive, therapeutic targetable, mechanism ope

225 Immunosuppressive therapies (ie, intravenous cyclophosph

226 Immunosuppressive therapies are effective, but reduced n

227 recalcitrant chronic itch that failed other immunosuppressive therapies markedly improve when treate

228 es, and previous treatment with at least two immunosuppressive therapies or one immunosuppressive the

229 or 6-12 months after discontinuation of such immunosuppressive therapies to protect against HBV react

230 of anti-HLA IgG with FcMonoIgG may minimize immunosuppressive therapies, maximize the number of dono

231 Despite advances in immunosuppressive therapies, the rate of chronic transpl

232 osporin A (CsA) or FK506 is a cornerstone of immunosuppressive therapies.

233 ity from infectious diseases, independent of immunosuppressive therapies.

234 presence of immunocompromising conditions or immunosuppressive therapies.

235 Adults with autoimmune disease treated with immunosuppressive therapy (biologic or nonbiologic) were

236 Growth factors can be combined with immunosuppressive therapy (IST) and may improve response

237 rm graft survival that necessitates lifelong immunosuppressive therapy after renal transplant.

238 least two immunosuppressive therapies or one immunosuppressive therapy and chronic intravenous immuno

239 al systemic toxicities of corticosteroid and immunosuppressive therapy and death.

240 risk is related to intensity and duration of immunosuppressive therapy and inversely to recipient age

241 susceptibility to infection, and response to immunosuppressive therapy are influenced in part by his/

242 BACKGROUND AND AIMS: Immunosuppressive therapy for inflammatory bowel disease

243 In the Supportive Versus Immunosuppressive Therapy for the Treatment of Progressi

244 We assessed the longitudinal requirement for immunosuppressive therapy in 339 patients treated with t

245 Although current immunosuppressive therapy in kidney transplant recipient

246 thway, allows for calcineurin-inhibitor free immunosuppressive therapy in kidney transplantation but

247 t that Rtx might replace St-Cp as first-line immunosuppressive therapy in patients with idiopathic me

248 risk of HBVr under different combinations of immunosuppressive therapy in rheumatic patients.

249 ng cell type for use as a cell-based adjunct immunosuppressive therapy in solid organ transplant reci

250 utcomes, uveitis patients receiving systemic immunosuppressive therapy may experience a deterioration

251 patients in a prospective phase 1-2 study of immunosuppressive therapy plus eltrombopag.

252 The intensive and prolonged immunosuppressive therapy required to prevent or treat g

253 d in candidate patients for chemotherapy and immunosuppressive therapy requires further investigation

254 Belatacept-based immunosuppressive therapy resulted in higher and more se

255 ith the use of an intensified posttransplant immunosuppressive therapy starting at day 0 combined wit

256 The addition of eltrombopag to immunosuppressive therapy was associated with markedly h

257 We combined standard immunosuppressive therapy with eltrombopag in previously

258 s were undergoing varied mono or combination immunosuppressive therapy, including 36 who were receivi

259 NAC, without concurrent plasma exchange and immunosuppressive therapy, is effective in preventing an

260 s of HBV-infected persons, persons requiring immunosuppressive therapy, persons with end-stage renal

261 ance between infectious risk and response to immunosuppressive therapy, such as that required for aut

262 n alpha-N-acetylglucosaminidase (NAGLU) plus immunosuppressive therapy.

263 mmation necessitating corticosteroid-sparing immunosuppressive therapy.

264 peutic approach than the current practice of immunosuppressive therapy.

265 fections in the posttransplant period due to immunosuppressive therapy.

266 P = .009) than those receiving conservative/immunosuppressive therapy.

267 on, thereby encouraging prompt initiation of immunosuppressive therapy.

268 ound that this combined approach reverts the immunosuppressive TME and recruits CD8 T cells with an i

269 ell subpopulation whose function ranges from immunosuppressive to effector.

270 e-stage organ failure, followed by long-term immunosuppressive treatment according to graft-specific

271 ticularly in reducing the need for long-term immunosuppressive treatment after transplantation.

272 Less aggressive and more individualized immunosuppressive treatment and close clinical follow-up

273 e intensive screening and/or minimization of immunosuppressive treatment are probably required.

274 At 2-year follow-up, immunosuppressive treatment has not led to metabolic, on

275 WAHA required immunosuppressive treatment in 4 of the 6 patients.

276 ld be useful to predict prognosis and tailor immunosuppressive treatment of AHA.

277 ic factors of and analyze the association of immunosuppressive treatment with relapse of NS.

278 ti-HBc alone patients who are candidates for immunosuppressive treatment, such patients might not req

279 n of switched memory B cells, independent of immunosuppressive treatment, was protective against rela

280 ronic kidney disease and requiring long-term immunosuppressive treatment.

281 eurosarcoidosis (NS), and the association of immunosuppressive treatments with outcomes are unclear.

282 Among all kinds of immunosuppressive treatments, glucocorticoid in combinat

283 Despite the existence of a highly immunosuppressive tumor environment, adenovirus-infected

284 imal T-cell receptor (TCR) activation and an immunosuppressive tumor environment.

285 f transferred T cells, especially inside the immunosuppressive tumor microenvironment (TME), the effi

286 ay be a result of the presence of a uniquely immunosuppressive tumor microenvironment (TME).

287 romote tumor progression by: (i) inducing an immunosuppressive tumor microenvironment and angiogenesi

288 Low tumor immunogenicity and a strong immunosuppressive tumor microenvironment cause significa

289 how TAS contributes to the production of an immunosuppressive tumor microenvironment in pancreatic c

290 ancer therapy is hampered by elements of the immunosuppressive tumor microenvironment such as TGFbeta

291 Cs), to immunotherapies is attributed to the immunosuppressive tumor microenvironment that protects m

292 ion alleviates hypoxia, which reprograms the immunosuppressive tumor microenvironment toward immunost

293 e myeloma and is a critical component of the immunosuppressive tumor microenvironment.

294 t and antitumor immunity by ameliorating the immunosuppressive tumor microenvironment.

295 ave been limited to date, due in part to the immunosuppressive tumor microenvironment.

296 ly targeted to enhance the susceptibility of immunosuppressive tumors to various therapeutic regimens

297 d in solid tumours due in part to the strong immunosuppressive tumour microenvironment.

298 identify suitable target antigens, overcome immunosuppressive tumour microenvironments, reduce toxic

299 esenchymal stromal cells (MSCs) are strongly immunosuppressive via producing nitric oxide (NO) and kn

300 Other immunosuppressives were not toxic, neither changed TEER